Here’s an interesting review
of Daratumumab which came in the Oncologist newsletter this morning. Daratumumab
seems to be a rather valuable treatment; a shame that it is seen as a nuisance
in the lab as it interferes with blood group antibody screening…
This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England. One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
No comments:
Post a Comment